BioAtla, Inc. is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. A Phase 1 dose-escalation study evaluated BA3071 monotherapy followed by combination with nivolumab, conducted in 18 patients who had prior PD-1 failure and a median of at least three prior lines of treatment. Across the 6 cohorts (n = 16 evaluable patients), best overall response observed with two confirmed responses (one complete response [CR] and one partial response [PR].

nine stable disease (SD); One uveal melanoma patient remains on treatment for more than 12 cycles; Two cutaneous melanoma patients remain on treatment for more than 14 and 17 cycles, respectively; One small-cell lung carcinoma (SCLC) patient continues on treatment more than one year (>22 cycles); More specifically, in the 350 mg cohort in combination with 240 mg nivolumab (n = 5), meaningful clinical benefit was observed in three patients, including 1 CR, 1 PR, and 1 SD; The confirmed CR was observed in a heavily pre-treated patient with stage IV cervical cancer with three prior lines of therapy; The confirmed PR (54.3% tumor reduction) was observed in a highly pre-treated patient with stageIV cervical cancer with four prior lines of therapy; No grade 4 related treatment-emergent adverse events were observed among 18 treated patients; Two patients with immune-related adverse events (Grade 3) reported to date; Maximum tolerated dose was not reached; One DLT observed out of 3 patients who received 700 mg; further evaluation of 700 mg and potentially at 1000 mg is ongoing. A Phase 2 clinical study of BA3071 monotherapy and in combination with PD-1 inhibitor is currently underway. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates.

Examples of forward-looking statements include, among others, statements the company make regarding business plans and prospects; results, conduct, progress and timing of research and development programs and clinical trials; expectations with respect to enrollment and dosing in the clinical trials, and plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions. Factors that could cause actual results to differ include, among others: potential delays in clinical and pre-clinical trials; the uncertainty inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clical trials, regulatory submission dates, or regulatory approval updates, clinical trials, regulatory approval updates, clinical trials and regulatory meetings and regulatory submissions.Factors that could cause actual results to vary include, among others: potential delay in clinical and pre- clinical trials; the uncertainties inherent in research and development, include the ability to meet anticipated clinicalendpoints, commence and/or completion dates for Clical trials, regulatory submission date, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; dependence on the success of the CAB technology platform; ability to enroll patients in ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; reliance on third parties for the manufacture and supply of product candidates for clinical trials; reliance on third parties to conduct clinical trials and some aspects of clinical trials and some aspects of the study.